SOPH News
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026 SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026PR NewswireBOSTON and ROLLE, Switzerland, Oct. 20, 2026BOSTON and ROLLE, Switzerland, Oct. 20, 2026 /PRNewswire/ -- SOPHiA...
PR Newswire
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026 SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026PR NewswireBOSTON and ROLLE, Switzerland, Oct. 20, 2026BOSTON and ROLLE, Switzerland, Oct. 20, 2026 /PRNewswire/ -- SOPHiA...
PR Newswire
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score TechnologyPR NewswireBOSTON, Oct. 8, 2026BOSTON, Oct. 8, 2026...
PR Newswire
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
SOPHiA GENETICS Reports Second Quarter 2026 Results
SOPHiA GENETICS Reports Second Quarter 2026 Results SOPHiA GENETICS Reports Second Quarter 2026 Results PR Newswire BOSTON and ROLLE, Switzerland, Aug. 4, 2026 BOSTON andROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine...
PR Newswire
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies PR Newswire BOSTON and ROLLE, Switzerland, Aug. 4, 2026 BOSTON and ROLLE, Switzerland, Aug...
PR Newswire
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?
TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.
Zacks
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026 PR Newswire BOSTON and ROLLE, Switzerland, July 21, 2026 BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire...
PR Newswire
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting PR Newswire ROLLE, Switzerland, June 22, 2026 Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross...
PR Newswire
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to...
PR Newswire